Blueprint prices IPO above range, raises $147m
This article was originally published in Scrip
Executive Summary
Blueprint Medicines has priced its heavily oversubscribed initial public offering (IPO) of just over 8 million shares at $18.00 per share, above the initial range of $15-$17. This led to gross proceeds of $147m and a market capitalization of $465m, "a pleasing result for a young biotechnology company not in the immune-oncology space and with two drugs about to enter the clinic," noted Thilo Schroeder, partner at Blueprint investor Nextech Invest and former member of its board.
You may also be interested in...
Blueprint Lays Out Path To Early Approval In Small GIST Population
Blueprint Medicines will pursue an accelerated path to approval for its newly designated breakthrough therapy BLU-285 in the treatment of gastrointestinal stromal tumors in a small subset of patients.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.